Lyme disease can affect the central nervous system causing a B-cell-predominant lymphocytic pleocytosis. Since most reactions to infection in the cerebrospinal fluid (CSF) are typically T-cell predominant, a B-cell-predominant lymphocytosis raises concern for lymphoma. We present 3 Lyme neuroborreliosis cases in order to illustrate the challenging cytomorphological and immunophenotypic features of their CSF specimens. Three male patients who presented with central nervous system manifestations were diagnosed with Lyme disease. The clinical presentation, laboratory tests, CSF cytological examination and flow-cytometric studies were described for each case. CSF cytology showed lymphocytic pleocytosis with increased plasmacytoid cells and/or plasma cells. Flow cytometry showed the presence of polytypic B lymphocytes with evidence of plasmacytic differentiation in 2 cases. In all cases, Lyme disease was confirmed by the Lyme screening test and Western blotting. In such cases of Lyme neuroborreliosis, flow cytometry of CSF samples employing plasmacytic markers and cytoplasmic light-chain analysis is diagnostically helpful to exclude lymphoma.

Keywords:
Cerebrospinal fluid, Lyme disease, Neuroborreliosis, Lymphoma
1.
Lyme Disease, Centers for Disease Control and Prevention. Lyme Disease Data and Statistics. http://www.cdc.gov/lyme/stats/index.html (accessed June 20, 2015).
2.
Murray TS, Shapiro ED: Lyme disease. Clin Lab Med 2010;30:311-328.
3.
Halperin JJ: Lyme disease: a multisystem infection that affects the nervous system. Continuum (Minneap Minn) 2012;18:1338-1350.
4.
Agarwal R, Sze G: Neuro-lyme disease: MR imaging findings. Radiology 2009;253:167-173.
5.
Biesiada G, Czepiel J, Leśniak MR, Garlicki A, Mach T: Lyme disease: review. Arch Med Sci 2012;8:978-982.
6.
Walther EU, Seelos K, Bise K, Mayer M, Straube A: Lyme neuroborreliosis mimicking primary CNS lymphoma. Eur Neurol 2004;51:43-45.
7.
Sindern E, Malin JP: Phenotypic analysis of cerebrospinal fluid cells over the course of Lyme meningoradiculitis. Acta Cytol 1995;39:73-75.
8.
Razavi-Encha F, Fleury-Feith J, Gherardi R, Bernaudin JF: Cytologic features of cerebrospinal fluid in Lyme disease. Acta Cytol 1987;31:439-440.
9.
Szyfelbein WM, Ross JS: Lyme disease meningopolyneuritis simulating malignant lymphoma. Mod Pathol 1988;1:464-468.
10.
Kieslich M, Fiedler A, Driever PH, Weis R, Schwabe D, Jacobi G: Lyme borreliosis mimicking central nervous system malignancy: the diagnostic pitfall of cerebrospinal fluid cytology. Brain Dev 2000;22:403-406.
11.
Bahrain H, Laureno R, Krishnan J, Aggarwal A, Malkovska V: Lyme disease mimicking central nervous system lymphoma. Cancer Invest 2007;25:336-339.
12.
Saggese CE, Cecotti L, Lazzarino de Lorenzo LG: Neuroborreliosis and CNS lymphoma: what is the nexus? Neurol Sci 2013;34:2253-2254.
13.
Jahnke K, Korfel A, O'Neill BP, Blay JY, et al: International study on low-grade primary central nervous system lymphoma. Ann Neurol 2006;59:755-762.
14.
Fassas ABT, Muwalla F, Berryman T, et al: Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extra-medullary manifestations. Br J Haematol 2002;117:103-108.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.